Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking oral presentation at the American Academy of Allergy Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, CA.1,2
Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
Positive high-level results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC (“AstraZeneca” or the “Company”) (
NASDAQAZN) and reminds investors of the Feb. 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
AZN Deadline: Rosen Law Firm Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (
NASDAQAZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
Deadline Soon: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 21, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (
NASDAQAZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZenecaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response (pCR) in muscle-invasive bladder cancer (MIBC). Patients were treated with four cycles of IMFINZI in combination with neoadjuvant chemotherapy before radical cystectomy (surgery to remove the bladder) followed by eight cycles of IMFINZI monotherapy.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZenecaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the FirmNEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Innovative Industrial Properties, Inc. (
NYSEIIPR), AstraZeneca PLC
NASDAQ: AZNNASDAQAZN)
(NASDAQ:FTAINASDAQFTAI
, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or the “Company”) (
NASDAQAZN) for violations of the federal securities laws on behalf of investors who purchased or acquired AstraZeneca common stock between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or the “Company”) (
NASDAQAZN) for violations of the federal securities laws on behalf of investors who purchased or acquired AstraZeneca common stock between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the FirmNEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (
NASDAQBIOA), AstraZeneca PLC
NASDAQ: AZNNASDAQAZN)
(NASDAQ:FTAINASDAQFTAI
, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or the “Company”) (
NASDAQAZN) for violations of the federal securities laws on behalf of investors who purchased or acquired AstraZeneca common stock between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, IIPR, Block, and Crocs and Encourages Investors to Contact the FirmNEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of AstraZeneca PLC (
NASDAQAZN), Innovative Industrial Properties, Inc.
NYSE:IIPRNYSEIIPR)
(NYSE: SQNYSESQ
, and Crocs, Inc. (NASDAQ: CROXNASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZenecaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their Options
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by a Food and Drug Administration (FDA)-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the FirmNEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or the “Company”) (
NASDAQAZN) for violations of the federal securities laws on behalf of investors who purchased or acquired AstraZeneca common stock between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”).
Robbins LLP Encourages AZN Shareholders with Large Losses to Seek Counsel in the AstraZeneca PLC Class ActionSAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (
NASDAQAZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology."
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZenecaFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AstraZenecaTo Contact Him Directly To Discuss Their Options
